These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 32323194

  • 41. Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.
    Maegawa H, Tobe K, Tabuchi H, Nakamura I, Uno S.
    Expert Opin Pharmacother; 2018 Mar; 19(4):327-336. PubMed ID: 29388470
    [Abstract] [Full Text] [Related]

  • 42. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
    Oguma T, Kuriyama C, Nakayama K, Matsushita Y, Yoshida K, Kiuchi S, Ikenaga Y, Nakamaru Y, Hikida K, Saito A, Arakawa K, Oka K, Ueta K, Shiotani M.
    J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
    [Abstract] [Full Text] [Related]

  • 43. The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension.
    Bryson A, Jennings PE, Deak L, Paveliu FS, Lawson M.
    Expert Opin Pharmacother; 2016 Jul; 17(10):1309-16. PubMed ID: 27181910
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
    Nakamura I, Maegawa H, Tobe K, Uno S.
    Adv Ther; 2019 Apr; 36(4):923-949. PubMed ID: 30767112
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.
    Yokote K, Terauchi Y, Nakamura I, Sugamori H.
    Expert Opin Pharmacother; 2016 Oct; 17(15):1995-2003. PubMed ID: 27477242
    [Abstract] [Full Text] [Related]

  • 48. Teneligliptin : expectations for its pleiotropic action.
    Morishita R, Nakagami H.
    Expert Opin Pharmacother; 2015 Feb; 16(3):417-26. PubMed ID: 25597385
    [Abstract] [Full Text] [Related]

  • 49. Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes.
    Hashikata T, Yamaoka-Tojo M, Kakizaki R, Nemoto T, Fujiyoshi K, Namba S, Kitasato L, Hashimoto T, Kameda R, Maekawa E, Shimohama T, Tojo T, Ako J.
    Heart Vessels; 2016 Aug; 31(8):1303-10. PubMed ID: 26266630
    [Abstract] [Full Text] [Related]

  • 50. Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design.
    Imazu M, Nakano A, Ito S, Hamasaki T, Kitakaze M, TOPLEVEL investigators and study coordinators.
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):363-370. PubMed ID: 30850916
    [Abstract] [Full Text] [Related]

  • 51. Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes.
    Aso Y, Kase M, Sagara M, Sakurai S, Iijima T, Tomaru T, Jojima T, Usui I.
    Am J Med Sci; 2020 Sep; 360(3):261-267. PubMed ID: 32540146
    [Abstract] [Full Text] [Related]

  • 52. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial).
    Terauchi Y, Yamada Y, Ishida H, Ohsugi M, Kitaoka M, Satoh J, Yabe D, Shihara N, Seino Y.
    Diabetes Obes Metab; 2017 Aug; 19(8):1188-1192. PubMed ID: 28294488
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study.
    Ji L, Li L, Ma J, Li X, Li D, Meng B, Lu W, Sun J, Liu Y, Takayanagi G, Wang Y.
    Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00222. PubMed ID: 33855222
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.
    Maegawa H, Tobe K, Tabuchi H, Nakamura I.
    Expert Opin Pharmacother; 2016 Oct; 17(15):1985-94. PubMed ID: 27463414
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
    Miya A, Nakamura A, Cho KY, Kawata S, Nomoto H, Nagai S, Sugawara H, Taneda S, Tsuchida K, Omori K, Yokoyama H, Takeuchi J, Aoki S, Kurihara Y, Atsumi T, Miyoshi H.
    J Diabetes Investig; 2021 Aug; 12(8):1395-1399. PubMed ID: 33325645
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.